Co-Managing Patients with Type 1 Diabetes and Cancer

Conor John Best, Sonali Thosani, Marjorie Ortiz, Celia Levesque, Sigi S. Varghese, Victor R Lavis

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.

Original languageEnglish (US)
Article number73
JournalCurrent Diabetes Reports
Volume16
Issue number8
DOIs
StatePublished - Aug 1 2016

Keywords

  • Cancer
  • Chemotherapy
  • Glucocorticoids
  • Hyperalimentation
  • Targeted cancer therapy
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Co-Managing Patients with Type 1 Diabetes and Cancer'. Together they form a unique fingerprint.

Cite this